| Symbol | LXEO |
|---|---|
| Name | LEXEO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 345 PARK AVENUE SOUTH,6TH FLOOR, NEW YORK, New York, 10010, United States |
| Telephone | 212-547-9879 |
| Fax | — |
| — | |
| Website | https://www.lexeotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001907108 |
| Description | Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreichs ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000947871-26-000801 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097207 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003428 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001011438-26-000515 <b>Size:</b> 9 KB
Read moreLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Read moreLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Read moreAltschuler Steven 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002
Read moreAgger Mette Kirstine 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002
Read moreCOOPERSTONE BRENDA 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002
Read moreDIAZ REINALDO M 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07721025 | Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy | Phase2 | Friedreich Ataxia | Recruiting | 2026-06-25 | 2032-06-01 | ClinicalTrials.gov |
| NCT06865482 | Clinical Course Of Disease In Participants With FA-CM | — | Friedreich Ataxia | Recruiting | 2025-09-30 | 2027-09-01 | ClinicalTrials.gov |
| NCT07050160 | Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due… | — | Arrhythmogenic Cardiomyopathy | Enrolling_By_Invitation | 2025-08-29 | 2030-08-01 | ClinicalTrials.gov |
| NCT06109181 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | Phase1 | Arrhythmogenic Cardiomyopathy | Active_Not_Recruiting | 2024-02-29 | 2027-03-01 | ClinicalTrials.gov |
| NCT06976606 | A Study to Assess Real-world Patient Characteristics and Clinical Course for Sy… | — | Arrhythmogenic Cardiomyopathy | Recruiting | 2024-01-23 | 2027-09-01 | ClinicalTrials.gov |
| NCT05400330 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease | Phase1 | Alzheimer Disease | Active_Not_Recruiting | 2023-05-08 | 2028-11-01 | ClinicalTrials.gov |
| NCT05445323 | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia | Phase1 | Friedreich Ataxia | Active_Not_Recruiting | 2022-08-24 | 2029-09-01 | ClinicalTrials.gov |
| NCT03634007 | Gene Therapy for APOE4 Homozygote of Alzheimer's Disease | Phase1 | Alzheimer Disease | Completed | 2019-11-06 | 2024-11-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Usual Care | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT07721025 |
| LX2006 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT07721025 |
| LX1001 | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05400330 |
| LX1001 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03634007 |
| LX2020 | Other | Phase PHASE1 | Arrhythmogenic Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06109181 |
| High Dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |
| Mid Dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |
| Low dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |